絞り込み

17065

広告

Rescue of AAV production by shRNA cotransfection.

著者 Guimaro MC , Afione S , Tanaka T , Chiorini J
Hum Gene Ther.2020 Mar 15 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

AAV vector technology is rapidly advancing and becoming the leading vector platform in the field of gene therapy but also a useful tool for functional genomic studies of novel proteins. As most vectors utilize constitutive promoters, this results in transgene expression during production. Depending on the transgene product, this could induce proapoptotic, cytostatic, or other unknown effects that interfere with producer cell function and therefore reduce viral vector yield. This can be a major limitation when trying to characterize poorly described genes. We describe the novel use of shRNA encoding plasmids cotransfected during packaging to limit the expression of the cytotoxic transgene product. This allowed the production of an otherwise unpackageable vector. The approach is simple, versatile, does not require modification of the vector plasmid, and should be easily adaptable to almost any transgene with minimal cost.
PMID: 32174180 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード